Scarica l'app Stockscreener
0.693
0.00%
0.00
Dopo l'orario di chiusura:
.68
-0.013
-1.88%
Precedente Chiudi:
$0.693
Aprire:
$0.688
Volume 24 ore:
142.47K
Relative Volume:
0.14
Capitalizzazione di mercato:
$35.89M
Reddito:
-
Utile/perdita netta:
$-81.22M
Rapporto P/E:
-0.2341
EPS:
-2.96
Flusso di cassa netto:
$-74.41M
1 W Prestazione:
+1.55%
1M Prestazione:
-1.01%
6M Prestazione:
-35.23%
1 anno Prestazione:
-22.13%
Intervallo 1D:
$0.6762
$0.6992
Intervallo di 1 settimana:
$0.655
$0.7025
Portata 52W:
$0.62
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
Nome
Xilio Therapeutics Inc
Settore
Industria
Telefono
617-833-1027
Indirizzo
828 WINTER STREET, WALTHAM
Confronta XLO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.693 | 35.89M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-12-21 | Iniziato | Chardan Capital Markets | Buy |
| 2022-01-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-16 | Iniziato | Cowen | Outperform |
| 2021-11-16 | Iniziato | Guggenheim | Buy |
| 2021-11-16 | Iniziato | Morgan Stanley | Overweight |
| 2021-11-16 | Iniziato | Raymond James | Outperform |
Mostra tutto
Xilio Therapeutics Inc Borsa (XLO) Ultime notizie
Xilio Therapeutics Executives Increase Holdings - TradingView
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World
Xilio Therapeutics Expands Authorized Shares at Annual Meeting - TipRanks
Xilio Therapeutics Appoints Akintunde Bello to Board of Directors - citybiz
Xilio Therapeutics appoints oncology veteran Akintunde Bello to board By Investing.com - Investing.com South Africa
Xilio Therapeutics expands board, elects new director - Investing.com Australia
Xilio Therapeutics expands board, elects new director By Investing.com - Investing.com South Africa
Xilio Therapeutics Expands Board with New Director - TipRanks
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - The Manila Times
Xilio Therapeutics appoints oncology veteran Akintunde Bello to board - Investing.com
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., To Its Board Of Directors - MarketScreener
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of Directors - Nasdaq
Bristol Myers Squibb Oncology Leader Joins Xilio Board: Key Boost for Novel Cancer Immunotherapy Programs - Stock Titan
Leadership Experience 2025: Starbucks Rallies 14,000 North America Coffeehouse Leaders to Accelerate its 'Back to Starbucks' Strategy - The Globe and Mail
Uranium Royalty Corp. Announces U.S.$30 Million Bought Deal Financing - The Globe and Mail
Musk-Trump Messy Breakup Wipes Out $150B in TSLA Stock: What's Next? - The Globe and Mail
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering - GlobeNewswire
Xilio Therapeutics Announces $50 Million Public Offering and Potential $150 Million in Total Gross Proceeds - Nasdaq
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering - GlobeNewswire Inc.
Market Analysis: June 4th, 2025 - The Globe and Mail
International Resources Holding Enters into Agreement to Acquire Majority Interest in Alphamin Resources Corp. from Tremont Master Holdings - The Globe and Mail
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Biotech Startup Xilio Awards $194K Worth of Stock Options Under Nasdaq Compliance Plan - Stock Titan
Xilio Therapeutics Inc (NASDAQ: XLO) Is Down -26.69% Year-To-Date, But Analysts Find Room For A Price Rally - Stocksregister
Form 424B5 Xilio Therapeutics, Inc. - StreetInsider
Xilio Therapeutics announces public offering of warrants By Investing.com - Investing.com South Africa
Xilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug Trial - MSN
Xilio Therapeutics tumbles after $50 mln equity offering - TradingView
Xilio Therapeutics (XLO) Launches Public Offering of Warrants | - GuruFocus
Xilio Therapeutics announces pricing of $50 million public offering - MSN
Xilio Therapeutics (XLO) Launches Public Offering of Warrants | XLO Stock News - GuruFocus
Xilio Therapeutics (XLO) Stock Dips Following Public Offering Announcement - GuruFocus
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering - The Manila Times
Xilio Therapeutics Secures $150M Potential Funding Through Strategic Warrant Offering for Cancer Therapies - Stock Titan
Xilio Therapeutics Announces Proposed Public Offering - marketscreener.com
Xilio Therapeutics (XLO) Launches Public Offering for Warrants | - GuruFocus
SEC Form 424B5 filed by Xilio Therapeutics Inc. - Quantisnow
Xilio Therapeutics drops on equity raise plans - TradingView
Xilio Therapeutics Presents Phase 2 Trial Data Update - TipRanks
Xilio Therapeutics announces public offering of warrants - Investing.com
Xilio Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Pre-Funded Warrants and Series A, B, and C Warrants - Nasdaq
Immuno-Oncology Biotech Xilio Therapeutics Unveils Complex Public Offering With Multiple Warrant Series - Stock Titan
Xilio Therapeutics (XLO) Reveals Positive Phase 2 Trial Data for Cancer Treatment | XLO Stock News - GuruFocus
Xilio Therapeutics Announces Updated Phase 2 Data for - GlobeNewswire
Xilio Therapeutics Reports Preliminary 26% Objective Response Rate in Phase 2 Trial of Vilastobart Combined with Atezolizumab for Metastatic MSS Colorectal Cancer - Nasdaq
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - The Manila Times
Xilio Therapeutics Announces Updated Phase 2 Data For Vilastobart, A Tumor-Activated Anti-Ctla-4, In Combination With Atezolizumab In Patients With Metastatic Microsatellite Stable Colorectal Cancer - marketscreener.com
Breakthrough: New Immunotherapy Achieves 26% Response Rate in Hard-to-Treat Colorectal Cancer Patients - Stock Titan
Xilio Therapeutics Reports Q1 2025 Financial Results - TipRanks
Thinking Of Buying Xilio Therapeutics Inc (NASDAQ: XLO) Stock? Here Is What You Should Know - Stocksregister
Xilio Therapeutics (NASDAQ:XLO) Upgraded at Wall Street Zen - Defense World
Xilio Therapeutics Inc Azioni (XLO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xilio Therapeutics Inc Azioni (XLO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shannon James Samuel | Director |
Jun 17 '25 |
Buy |
0.69 |
25,000 |
17,215 |
70,000 |
| Russo Rene | PRESIDENT AND CEO |
Jun 16 '25 |
Buy |
0.68 |
36,289 |
24,680 |
281,172 |
| Frankenfield Christopher James | Chief Financial Officer |
Jan 02 '25 |
Sale |
0.98 |
6,954 |
6,841 |
12,421 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING |
Jan 02 '25 |
Sale |
0.98 |
1,803 |
1,774 |
3,197 |
| GILEAD SCIENCES, INC. | 10% Owner |
Dec 18 '24 |
Buy |
1.04 |
1,759,978 |
1,830,377 |
9,105,451 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):